Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Clinical trial NCT06304441 · RECRUITING

Trial details

NCT number: NCT06304441
Sponsor: Guangzhou Medical University
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Leptomeningeal Metastasis

Start date: 2024-04-18
Primary completion: 2026-06-20
Enrollment: 100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.